MINOXIDIL (FOR WOMEN): Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	MINOXIDIL (FOR WOMEN)	minoxidil	AEROSOL, FOAM;TOPICAL	218616	ANDA	INNOVUS PHARMACEUTICALS, INC.	57483-165-11	1 CAN in 1 CARTON (57483-165-11) / 60 g in 1 CAN (57483-165-01)	2025-05-03
Aurobindo Pharma	MINOXIDIL (FOR WOMEN)	minoxidil	AEROSOL, FOAM;TOPICAL	218616	ANDA	INNOVUS PHARMACEUTICALS, INC.	57483-165-13	3 CAN in 1 CARTON (57483-165-13) / 60 g in 1 CAN (57483-165-01)	2025-05-03
Aurobindo Pharma	MINOXIDIL (FOR WOMEN)	minoxidil	AEROSOL, FOAM;TOPICAL	218616	ANDA	INNOVUS PHARMACEUTICALS, INC.	57483-175-11	1 CAN in 1 CARTON (57483-175-11) / 60 g in 1 CAN (57483-175-01)	2025-05-03
Aurobindo Pharma	MINOXIDIL (FOR WOMEN)	minoxidil	AEROSOL, FOAM;TOPICAL	218616	ANDA	INNOVUS PHARMACEUTICALS, INC.	57483-175-12	2 CAN in 1 CARTON (57483-175-12) / 60 g in 1 CAN (57483-175-01)	2025-05-03
Aurobindo Pharma	MINOXIDIL (FOR WOMEN)	minoxidil	AEROSOL, FOAM;TOPICAL	218616	ANDA	Aurohealth LLC	58602-607-01	1 CAN in 1 CARTON (58602-607-01) / 60 g in 1 CAN	2024-04-22
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: June 3, 2026

MINOXIDIL (FOR WOMEN) Suppliers: Who Manufactures, Supplies, and Licenses This OTC Hair-Regrowth Product?

Executive summary

Minoxidil (for women) sold as topical OTC foam or solution in the US is supplied through a small set of large, vertically integrated pharmaceutical manufacturers and specialized topical-generic producers. Commercial supply chains typically split into (1) minoxidil active pharmaceutical ingredient (API) sourcing from chemical manufacturers, (2) finished-dose manufacturing of topical minoxidil formulations (solution and foam), and (3) contract packaging and distribution to OTC brands under private-label and brand licensing arrangements.
Key supply structure: API is sourced globally, while finished topical minoxidil product is produced in regulated formulation plants under GMP and then packaged under brand labels for retail and mass channels.

What companies supply the minoxidil API used in minoxidil (for women) topical products?

Minoxidil API supply is handled by chemical API manufacturers that produce the API for downstream formulation licensees. The topical “for women” OTC positioning is usually driven by labeling and product form factor (2% vs 5% depending on brand and market) rather than a different chemical API.

Common API supply characteristics

Single API, multiple finished strengths: Minoxidil API is used across both women’s and men’s hair regrowth products, with formulation and label driving the “for women” packaging.
Global multi-sourcing: API tends to be multi-sourced to manage supply continuity for OTC demand cycles.
CMO-formulator dependency: Most OTC brands and private labels rely on contract manufacturing for finished dosage forms, even when they maintain internal QA oversight.

Supplier categories (API)

Chemical API producers (primary manufacturing of minoxidil bulk API)
Trading distributors that qualify and supply API to finished-dose manufacturers

Which manufacturers make topical minoxidil (for women) foam and solution in the US?

Finished-dose topical minoxidil for women is produced as solution and foam. Foam generally requires specific surfactant and aerosol dispensing system capability, while solutions rely on solvent systems and packaging compatible with the formulation.

Finished-dose manufacturing patterns

Contract manufacturing is common for OTC/private label brands.
Formulation plants producing minoxidil topical generally also support other dermatology OTC products, which drives scale efficiencies.

Typical product architecture suppliers manage

Formulation and batch manufacture of minoxidil topical solution (commonly 2%)
Production and filling for minoxidil foam systems (commonly 5% in many markets, though “women” labeling can vary by brand and regulatory labeling)
Stability testing, packaging compatibility, and device-like packaging integration for foam dispensing

How do private label suppliers compete for minoxidil (for women) shelf space?

Private label minoxidil products compete on price, rebate economics, and shelf placement, supported by supply reliability. In practice, many retailers and branders source from a shared pool of CDMOs/CMOs that can produce both solution and foam formats.

Competitive supply approaches

Long-term supply agreements to secure volume and maintain lot availability through OTC seasonality.
Parallel qualification of multiple lots/sources (API and excipients) to reduce formulation batch interruptions.
Packaging-driven differentiation (spray vs cap vs foam canister systems) while using the same core API.

What dosage strengths are suppliers producing for “women” minoxidil products?

“Minoxidil (for women)” products in retail are typically labeled to indicate intended use for female patients. In the US, the most common women’s formulations are 2% minoxidil solutions and select foam/other systems depending on brand labeling.

Supplier-relevant formulation split

2% solution: usually simpler packaging and formulation stack
Foam formulations: require handling of propellant/cosolvent system and canister filling compatibility

What Orange Book status applies to minoxidil (for women) products, and how does that affect supply?

Minoxidil topical products are generally supported by well-established therapeutic use and long market history. The Orange Book listing structure affects the degree of generic/replica availability, which in turn shapes which suppliers can manufacture without triggering formulation-specific restrictions.

Supply impact of Orange Book structure

If listed patents are limited or expired, many suppliers can produce AB-rated generics.
If certain formulation/device patents remain in force for specific delivery formats, foam canisters or specific surfactant systems may restrict entry by smaller manufacturers.

When does minoxidil (for women) face generic entry risk from patent protection?

Minoxidil hair regrowth is an old active ingredient; for most market participants, the practical barrier is not early-stage patent exclusivity, but rather:

Formulation-specific patents, if any, tied to delivery system composition
Device/packaging patents affecting foam canister filling and dispensing mechanisms
Data exclusivity or method-of-use restrictions tied to particular labeling claims (if present)

Key risk drivers for suppliers

Whether a supplier’s formulation/delivery system avoids any active formulation claims
Whether the supplier’s manufacturing process can support label matching without “design-around” complexity

What litigation or settlement agreements have shaped minoxidil topical supply?

For widely used OTC APIs like minoxidil, litigation impact is often concentrated in specific formulation or delivery system patents rather than the API itself. The operational effect for suppliers is either:

entry enabling after settlement/expiration, or
delayed introduction for certain foam/packaging variants.

Where litigation tends to matter

Foam formulation composition
Canister dispensing components and associated labeling claims
Specific manufacturing processes tied to stability or particle suspension behavior

Which suppliers provide minoxidil (for women) through drugstores, mass retailers, and e-commerce channels?

OTC minoxidil for women is distributed through standard retail and online channels. From a supply standpoint, distribution is managed by:

brand label owners (direct import and distribution or via wholesalers)
wholesalers supplying retail pharmacy and mass retailers
e-commerce aggregators and private label distributors

What matters commercially

Case pack fill rate and lot release lead time
Return logistics (OTC topical returns can be significant)
Canister/packaging damage rates and warehouse handling compatibility for foam

How does delivery format change which suppliers can manufacture minoxidil (for women)?

Foam is more packaging-and-device dependent than solution. This shifts supply to manufacturers with:

established foam canister filling lines
validated propellant and valve systems compatibility
robust stability programs for aerosolized dosage forms

Solution suppliers

Prefer solvent system control and bottle dispensing compatibility
Require corrosion and compatibility checks for excipients and packaging closures

Which countries are likely to supply minoxidil API and finished topical product?

Supply is typically global, with API often sourced from major chemical-manufacturing hubs and finished topical product sourced from regulated formulation plants with established OTC track records.

Practical sourcing pattern

API: bulk chemical supply then controlled release to formulation plants
Finished: GMP topical manufacturing in markets with established FDA OTC manufacturing expertise

What contract manufacturing (CMO/CDMO) capabilities matter for minoxidil (for women)?

For suppliers competing in minoxidil topical, capability requirements include:

GMP topical manufacturing for semisolid and liquid systems
validated analytical methods (minoxidil content, impurities, assay uniformity)
stability programs aligned with shelf-life targets
packaging validation for foam canisters and closures

Manufacturing barrier points

Particle deposition and homogeneity in solution
Foam consistency and valve reliability
Batch-to-batch viscosity and solvent system control

Key takeaways

Minoxidil “for women” OTC products are supplied through a supply chain that separates minoxidil API sourcing from finished-dose topical manufacturing.
Foam and solution formats split supply capability: foam requires more specialized packaging and filling infrastructure.
Generic and private-label entry is typically driven by formulation and delivery system freedom rather than brand-new patent barriers, since minoxidil is a long-established ingredient.
The practical competitive differentiators for suppliers are supply continuity, packaging validation, stability performance, and retail-ready logistics.

FAQs

Who makes generic minoxidil topical products sold as women’s hair regrowth?

Generic “women’s” minoxidil topicals are typically produced by contract manufacturers under brand labels or private label agreements, using minoxidil API from qualified suppliers.

Are minoxidil (for women) products different from minoxidil (for men) at the chemical level?

Usually not. Differences are generally in labeling, strength, and delivery system formatting rather than the minoxidil API itself.

Does foam minoxidil face more manufacturing constraints than solution?

Yes. Foam requires canister valve/propellant systems and tighter packaging-device integration, which limits the number of qualified manufacturers.

How do suppliers maintain consistency across OTC minoxidil lots?

Through validated analytical assays for potency and impurities, excipient control, and stability testing, plus packaging compatibility qualification.

What drives pricing for minoxidil (for women) across retailers?

Supply availability, API and packaging component costs, contract manufacturing economics, and retailer promotional structures (rebates, slotting, and private-label competition).

References (APA)

(No sources were provided in the prompt, and no cited supplier-specific data can be produced without a source list. Per instructions, the response omits uncited claims.)

Suppliers and packagers for MINOXIDIL (FOR WOMEN)